Abstract: The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular diseases, fibrosis (e.g. cardiac fibrosis), inflammatory or autoimmune diseases and conditions, conditions of excessive or abnormal vascularization (e.g. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia, human immunodeficiency virus (HIV) infection and obesity. Further provided are said compounds for use in methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide, as well as for use in in vitro methods for identifying an agent useful as a therapeutic. An exemplary compound is e.g. WW-1.

Abstract: The present technology provides rechargeable alkali metal-sulfur galvanic cells and batteries incorporating such cells as well as methods of using such cell and batteries. The present galvanic cells provide high specific energy and high power at lower cost than conventional alkali metal-sulfur cells.

Abstract: The application discloses selective ACKR3 modulating peptides comprising amino acid sequence FGGX1MRRX2 (SEQ ID NO: 1), wherein X1 is F or W; X2 is K, V or F; and wherein the peptides have a length of at most 15 amino acids; fusion proteins comprising the peptides as taught herein; nucleic acids encoding the peptides as taught herein; nucleic acid expression cassettes and vectors comprising the nucleic acid as taught herein; and pharmaceutical compositions comprising the peptide as taught herein or the nucleic acid as taught herein. Further provided are the peptide as taught herein for use as a medicament; methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide using the peptide as taught herein; and in vitro methods for identifying an agent useful as a therapeutic using the peptide as taught herein.

Abstract: The present technology provides rechargeable alkali metal-sulfur galvanic cells and batteries incorporating such cells as well as methods of using such cell and batteries. The present galvanic cells provide high specific energy and high power at lower cost than conventional alkali metal-sulfur cells.

Abstract: The invention relates to heterocyclic sulfonamide derivatives and their use in the treatment and prophylaxis of autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal and metabolic mediated diseases, and to compositions containing said derivatives and processes for their preparation.

Abstract: A machine to perform operations in a field includes a memory including instructions and processing circuitry that is configured by the instructions to receive coverage data from a server, where the coverage data is indicative of operations executed by another machine in the field. The processing circuitry that is further configured by the instructions to determine, using the coverage data, a strategy for performing operations in the field, where the strategy reduces the likelihood of the machine from processing an area of the field that was previously processed by the other machine. The processing circuitry that is further configured by the instructions to actuate the machine according to the strategy.

Abstract: Disclosed in some examples are methods, systems, and machine-readable mediums to collect Global Navigation Satellite System (GNSS) corrections reliably via multiple network links. In some examples, the GNSS corrections are obtained at a GNSS correction server via multiple network links. The GNSS corrections are processed at the GNSS correction server via a voting algorithm that determines the optimal instance of the GNSS correction to forward to the remote GNSS Client.

Abstract: Methods and systems for determining a temperature of goods in a temperature controlled unit are disclosed. Raw temperature data is received for a first iteration. The raw temperature data indicates an air temperature inside the temperature controlled unit at the first iteration. A property value for a good stored in the temperature controlled unit is obtained. Based on the raw temperature data for the first iteration and the property value for the good, a first adjusted stored goods temperature is determined for the good. The first adjusted stored goods temperature for the good represents a first internal temperature of the good. Additional iterations are performed, where raw temperature data is received for a second iteration. Based on the raw temperature for the second iteration and the property value for the good, a second adjusted stored goods temperature is determined.

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: Disclosed in some examples are methods, systems and machine readable mediums to efficiently stream data across restricted networks. In some examples, this streamed data may be sent more efficiently using lower overhead protocols such as UDP. In order to bypass the aforementioned limitations on these lower overhead protocols, the client may send a periodic update message to the server. This update message maintains the openings in the network firewalls and updates the server on the client's status. This update message may be sent much less frequently than a typical TCP acknowledgement, and the lower overhead protocol may be a protocol that does not retransmit lost or corrupted packets—thereby eliminating unnecessary overhead. In some examples this streamed data may be GNSS correction data. In some examples, the client may be behind one or more network firewalls.

Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract: The present invention relates to improved processes for culturing bacteria, in particular to processes for perfusion suspension culturing of bacteria in a fermenter, wherein the culture medium including the bacteria is circulated over a separation system in alternating tangential flow, wherein the separation system removes a filtrate containing inhibitory metabolites from the culture medium.

Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: Methods and systems for determining a temperature of goods in a temperature controlled unit are disclosed. Raw temperature data is received for a first iteration. The raw temperature data indicates an air temperature inside the temperature controlled unit at the first iteration. A property value for a good stored in the temperature controlled unit is obtained. Based on the raw temperature data for the first iteration and the property value for the good, a first adjusted stored goods temperature is determined for the good. The first adjusted stored goods temperature for the good represents a first internal temperature of the good. Additional iterations are performed, where raw temperature data is received for a second iteration. Based on the raw temperature for the second iteration and the property value for the good, a second adjusted stored goods temperature is determined.

Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: A bearing lining has a bearing backing layer provided with a coating comprising a first overlay layer and a second overlay layer, the first overlay layer being provided between the bearing backing layer and the second overlay layer. The first and second overlay layers each comprise a matrix material and a soft-phase material that is substantially insoluble in the matrix and dispersed within the matrix as soft-phase particles. The first overlay layer comprises a higher proportion by weight of a grain size reduction additive than the second overlay layer.